Explain Why IV Cetirizine Shouldn't Be on Formulary

June 2020

IV cetirizine (Quzyttir) will be the first injectable "second-generation" antihistamine.

It will be an IV push...and is approved for acute urticaria. It's non-inferior to IV diphenhydramine for reducing itching.

Expect reps to tout IV cetirizine as less sedating.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Hazardous Meds Be Ready for Possible Changes to Your Hazardous Med Policy
Infectious Diseases Stay on Top of Treatment Options for COVID-19
Infectious Diseases Settle Debate About Vancomycin or Fidaxomicin for C. diff
Automated Dispensing Minimize Med Errors With Safe ADC Use
Allergic Reactions Address Barriers to Giving Epinephrine for Anaphylaxis
Practice Help Patients and Colleagues Understand Test Results
New Drugs Explain Why IV Cetirizine Shouldn't Be on Formulary
Dermatology Manage Skin Irritation Due to Handwashing and PPE
Anticoagulants Be Prepared to Treat and Prevent VTE Due to Cancer